Status:
UNKNOWN
The Contribution of Induced Glycolysis to the Exhaled Volatile Organic Compounds' (VOCs) Signature in Lung Cancer
Lead Sponsor:
Sheba Medical Center
Conditions:
Lung Cancer
Eligibility:
All Genders
18-95 years
Brief Summary
Lung cancer is the most lethal cancer, killing \~1.3 million people worldwide every year. Early diagnosis could increase its survival by 3-4 folds. Therefore the yield of screening for lung cancer is ...
Detailed Description
The Contribution of induced Glycolysis to the Exhaled Volatile Organic Compounds' (VOCs) Signature in Lung Cancer Abstract: Lung cancer is infamous for its cruel mortality rates as it is the most le...
Eligibility Criteria
Inclusion
- 50 individuals who currently suffer from lung cancer, who have not yet begun any medical treatment
- 20 individuals who have been defined as high-risk patients for lung cancer by the Research and Detection Unit for Thoracic malignancies at the Sheba Medical Center, Tel Hashomer, Israel
Exclusion
- individuals who suffer from diabetes
- Individuals who suffer from lung cancer, and are currently being treated
- minors ( under the age of 18)
Key Trial Info
Start Date :
September 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2015
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT01852838
Start Date
September 1 2013
End Date
April 1 2015
Last Update
February 21 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheba Medical Center
Ramat Gan, Ramat Gan, Israel, 52621